Beware of new warnings for contrast agents
FDA issues new warnings about Definity and Optison contrast agents
If you're administering the micro-bubble contrast agents Definity (Perflutren Lipid Microsphere, Bristol-Myers Squibb Medical Imaging) or Optison (Perflutren Protein-Type A Microspheres for Injection, GE Healthcare), beware that the FDA has just issued new labeling that warns that these products have not been tested for safety and efficacy when used with exercise or pharmacological stress. The agency also cautioned that the products are contraindicated among patients with unstable cardiopulmonary status. For more information, refer to
Q&A: Factors Showing Tirzepatide is More Beneficial Than Semaglutide | ASHP Midyear
Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed the benefits of tirzepatide compared with semaglutide.
